newswire, breaking biotechnology and pharma news

Friday, September 2, 2016

Zika Stocks To Watch; $AEMD, $BCRX, $CERS, $INO; Miami-Dade Mosquitoes Test Positive for Zika

Zika Stocks To Watch; $AEMD, $BCRX, $CERS, $INO; Miami-Dade Mosquitoes Test Positive for Zika

Zika Stocks Added: $OSUR, $SPB

Point Roberts, WA, September 2, 2016 –, a global news source and investor resource covering actively traded sectors including biotech and medical technology stocks, updates the Zika directory for investors following the sector as news from The Florida Department of Agriculture and Consumer Services shows test positive results in Miami-Dade.

Miami-Dade Mosquitoes Test Positive for Zika
Sep 1, 2016 TALLAHASSEE, Fla. — The Florida Department of Agriculture and Consumer Services has detected Zika in three mosquito samples from a small area in Miami Beach. The mosquitoes from Miami Beach that tested positive for Zika are from an area where increased trapping and intensified mosquito control measures are occurring due to the investigation of local transmission led by the Florida.Department of Health. Ninety-five additional samples have been submitted by Miami-Dade County after the date of the positive submission, and the mosquitoes have tested negative for Zika.

“This find is disappointing, but not surprising. Florida is among the best in the nation when it comes to mosquito surveillance and control, and this detection enables us to continue to effectively target our resources. Miami-Dade County, the City of Miami Beach, and state and federal partners will continue to work aggressively to prevent the spread of Zika,” stated Commissioner of Agriculture Adam H. Putnam.

The Florida Department of Agriculture and Consumer Services has tested more than 2,470 mosquito samples, consisting of more than 40,000 mosquitoes, since May, and these three samples are the first to test positive.

Full news:

Zika Virus Stocks
Aethlon Medical, Inc. (NasdaqCM: AEMD) creates innovative medical devices to address life-threatening diseases. The Aethlon ADAPT™ (Adaptive Dialysis-like Affinity Platform Technology) establishes the basis for a new class of therapeutics that target the rapid elimination of disease enabling particles from the circulatory system of treated patients.  The lead Aethlon ADAPT™ product is the Hemopurifier®, a device that addresses a broad-spectrum of viral pathogens as well as tumor-secreted exosomes that suppress the immune system of cancer patients.  Aethlon is also operating under two government contracts with the Defense Advanced Research Projects Agency (DARPA) related the development of a medical device to reduce the incidence of sepsis. Exosome Sciences, Inc. is a majority owned Aethlon subsidiary that is advancing exosome-based strategies to diagnose and monitor cancer and infectious disease progression. 
Aethlon Medical (Nasdaq: AEMD) Announces Zika Virus Data
In vitro studies that demonstrate the rapid capture of Zika virus by the Aethlon Hemopurifier
SAN DIEGO - August 11, 2016- Aethlon Medical, Inc. (Nasdaq: AEMD), a developer of immunotherapeutic technologies to combat infectious disease and cancer, announced today that its researchers have completed in vitro studies that demonstrate the rapid capture of Zika virus by the Aethlon Hemopurifier®. The Hemopurifier® is a leading broad-spectrum treatment countermeasure against viral pathogens that are untreatable with or resistant to antiviral drug therapies. At present, the immunotherapeutic technology is being advanced through an FDA approved human feasibility study. The Zika studies, which were conducted with small-scale versions of the Hemopurifier®, demonstrated a 95% clearance of Zika virus from cell culture fluid in 5.5 hours and an approximate 50% clearance of Zika from human blood serum in 5 hours.
The studies were conducted with the Zika viral strain that has recently spread from South America to ravage Puerto Rico and likely responsible for the first wave of infections that have begun to occur in the United States. Zika has been declared a global health threat by the World Health Organization and is not addressed with a proven drug or vaccine therapy. According to the CDC, more than 7,300 Americans have been diagnosed with Zika virus infection, including 1,825 individuals in the continental U.S. and Hawaii. Researchers have linked Zika virus infection with Guillain-Barre syndrome, a severe neurological disorder that can cause paralysis. In pregnant women, Zika can cause Microcephaly, which results in babies being born with a small head and underdeveloped brain. Zika infection has also been associated with Arthrogryposis, a condition that results in deformities of joints in the arms and legs of newborns.
"As a result of our research team's validation of Zika capture, we have further reinforced the potential of our Hemopurifier® to be a first line of defense against the growing list of infectious viral pathogens that are not addressed with traditional drug or vaccine therapies," stated Aethlon Chairman and CEO, Jim Joyce.
BioCryst Pharmaceuticals (NASDAQ:BCRX) BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases.  BioCryst’s ongoing development programs include oral plasma kallikrein inhibitors for hereditary angioedema; BCX7353 and other second generation compounds, and BCX4430, a broad spectrum viral RNA polymerase inhibitor. In March the Company announced that results from a preclinical study of its broad spectrum antiviral BCX4430 in immune-deficient mice infected with Zika virus would be presented at a World Health Organization (WHO) meeting scheduled to take place March 7-9 in Geneva, Switzerland. The primary goal of the study was to assess the effect of BCX4430 treatment on survival through Day 28 in immune-deficient mice infected with the Zika virus. BCX4430 was administered by intramuscular (I.M.) injection twice a day beginning four hours prior to virus challenge and continuing for eight days; two dose levels were tested. In the standard dose BCX4430 group, 7 of 8 mice survived through Day 28. In the low dose BCX4430 group (n=8), and in control groups administered vehicle placebo (n=8) or ribavirin at two dose levels (n=16), no animals survived to Day 28. Overall survival for the standard dose level of BCX4430 was superior to both the placebo and the ribavirin treatment control groups (p < 0.0001). For both dose levels of BCX4430, median survival was superior to both control groups (>28 days for BCX4430 standard dose and 23 days for low dose) compared to 14 to 17 days for controls. This study was conducted at Utah State University, under the ongoing Animal Models of Infectious Disease Program at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. This program provides in vivo screening services for researchers, as part of a broader suite of preclinical services supported by NIAID. These services are part of NIAID’s infrastructure for responding to emerging infectious diseases, such as Zika virus, and allow for research to be quickly directed to support immediate public health needs.
Cerus Corp. (NasdaqGM: CERS) is a biomedical products company focused in the field of blood safety. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. In the United States, Cerus is seeking regulatory approval of the INTERCEPT Blood System for plasma and platelets. The INTERCEPT red blood cell system is in clinical development
GeneOne Life Science Inc. (KSE:011000.KS; KRX:011000.KR) a biopharmaceutical company, engages in the research and development of DNA vaccines to prevent and treat incurable diseases in South Korea and internationally. Its product pipeline includes VGX-3400, a DNA vaccine, which has completed Phase I clinical trials for the prevention of avian influenza; VGX-3500, a prophylactic pre-pandemic influenza DNA vaccine that is in Phase I clinical trials for protection against swine, avian, and seasonal influenza; and FLUPRIME, a trivalent influenza vaccine, which is in Phase I clinical trials for the prevention of the outbreak of seasonal flu. The company is also developing VGX-6150, a therapeutic DNA vaccine that is in Phase I clinical trials for the treatment of hepatitis C; and therapeutic DNA vaccines for the treatment of hepatitis B. In addition, it is involved in the contract manufacturing activities for various pre-clinical and clinical studies for institutions, universities, governments, and biotechnology companies. GeneOne Life Science Inc. has a collaboration with Inovio Pharmaceuticals, Inc. to test and advance a DNA-based vaccine for preventing and treating the emerging and virulent Zika virus infection. The company was formerly known as VGX International Inc.
GLAXOSMITHKLINE  PLC (NYSE:GSK) creates, discovers, develops, manufactures, and markets pharmaceutical products, such as vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company provides pharmaceutical products in various therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also offers consumer health products in total wellness, oral care, nutritional, and skin health areas. In addition, it provides prescription medicines; and paediatric and adult vaccines against various infectious diseases
Inovio Pharmaceuticals, Inc (NYSE MKT:INO) is revolutionizing the fight against cancer and infectious diseases. Our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. With an expanding portfolio of cancer immunotherapies and clinical studies, the company is advancing a growing product pipeline. Partners and collaborators include Roche, the University of Pennsylvania, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, US Dept. of Homeland Security, and University of Manitoba.

Intrexon Corporation (NYSE:XON) is Powering the Bioindustrial Revolution with Better DNA™ to create biologically-based products that improve the quality of life and the health of the planet. The Company's integrated technology suite provides its partners across diverse markets with industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA®.
OraSure Technologies, Inc. ( NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices  has been awarded a contract for up to $16.6 million in total funding from the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response’s Biomedical Advanced Research and Development Authority (BARDA) to advance the Company’s rapid Zika tests. The six-year, multi-phased contract includes an initial commitment of $7.0 million and options for up to an additional $9.6 million to fund the evaluation of additional product enhancements, and clinical and regulatory activities. The Company is expected to provide an update on guidance and timing during its next quarterly earnings call in November.
SANOFI-AVENTIS SA (NYSE:SNY; Paris: SAN.PA) a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme.
Spectrum Brands Holdings, Inc. (NYSE: SPB) Spectrum Brands Holdings, a member of the Russell 2000 Index, is a global consumer products company offering an expanding portfolio of leading brands providing superior value to consumers and customers every day. The Company is a leading supplier of consumer batteries, residential locksets, residential builders’ hardware, plumbing, shaving and grooming products, personal care products, small household appliances, specialty pet supplies, lawn and garden and home pest control products, personal insect repellents, and auto care products. Helping to meet the needs of consumers worldwide, our Company offers a broad portfolio of market-leading, well-known and widely trusted brands including Rayovac®, VARTA®, Kwikset®, Weiser®, Baldwin®, National Hardware®, Pfister®, Remington®, George Foreman®, Russell Hobbs®, Black+ Decker®, Tetra®, Marineland®, Nature’s Miracle®, Dingo®, 8-in-1®, FURminator®, IAMS®, Eukanuba®, Digest-eeze™, Healthy-Hide®, Littermaid®, Spectracide®, Cutter®, Repel®, Hot Shot®, Black Flag®, Liquid Fence®, Armor All®, STP® and A/C PRO®. Spectrum Brands' products are sold by the world's top 25 retailers and are available in more than one million stores in approximately 160 countries. Based in Middleton, Wisconsin, Spectrum Brands Holdings generated net sales of approximately $4.69 billion in fiscal 2015. Spectrum Brands, Inc. – Pet, Home & Garden Division, is a global leader in lawn and garden and home pest control products, and personal insect repellents. The company offers a broad portfolio of market-leading, trusted products from brands that include Spectracide®, Cutter®, Repel®, Hot Shot®, Black Flag® and Liquid Fence®.

Full biotech stocks directory :

About - News that Inspires Big Ideas
Sectors we cover in include mining, energy, renewable energy, water stocks, food and beverage (including organic and LOHAS, wine), defense and security, biotech, technology and mobile. We have also expanded our global coverage to include Latin American stocks, the Middle East, sports and entertainment.

Follow on Twitter!/Investorideas
Follow on Facebook

Investor Ideas Directories for global investors:
From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

Services for Publicly traded companies:

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: Disclosure: AEMD - August 11, 2016 - one month of PR. News publication and social media – two thousand five hundred

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: Global investors must adhere to regulations of each country.



No comments:

Post a Comment